Alpha 2.0
Login Register
» Articles » PMID: 10722513

In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-dalfopristin Against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -resistant Strains

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 2000 Mar 18
PMID 10722513
Citations 81
Authors
M J Rybak
E Hershberger
T MOLDOVAN
R G Grucz
Affiliations
Soon will be listed here.
Abstract

The in vitro activity of daptomycin was compared with those of vancomycin, linezolid, and quinupristin-dalfopristin against a variety (n = 203) of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and S. epidermidis (MRSA and MRSE, respectively), vancomycin-resistant enterococci (VRE), and vancomycin-intermediate S. aureus (VISA). Overall, daptomycin was more active against all organisms tested, except Enterococcus faecium and VISA, against which its activity was similar to that of quinupristin-dalfopristin. In time-kill studies with MRSA, MRSE, VRE, and VISA, daptomycin demonstrated greater bactericidal activity than all other drugs tested, killing > or =3 log CFU/ml by 8 h. Daptomycin may be a potential alternative drug therapy for multidrug-resistant gram-positive organisms and warrants further investigation.

Citing Articles

Real-World Clinical Characteristics and Outcomes with Daptomycin Use in Pediatric Patients: A Retrospective Case Series.

Persha H, Thacker S, Mediwala Hornback K, Alvira-Arill G, Lueking R, Morrisette T Antibiotics (Basel). 2024; 13(9).

PMID: 39335007 PMC: 11444134. DOI: 10.3390/antibiotics13090833.

Population pharmacokinetics and dosage optimization of linezolid in Chinese older patients.

Li Y, Fang Q, Wu Z, Huang S, Ge W, Shen J Eur J Clin Pharmacol. 2024; 80(9):1295-1304.

PMID: 38801422 DOI: 10.1007/s00228-024-03702-9.

In Vitro Activities of Oxazolidinone Antibiotics Alone and in Combination with C-TEMPO against Methicillin-Resistant Biofilms.

Ndukwe A, Qin J, Wiedbrauk S, Boase N, Fairfull-Smith K, Totsika M Antibiotics (Basel). 2023; 12(12).

PMID: 38136740 PMC: 10741017. DOI: 10.3390/antibiotics12121706.

A Study on Glycopeptide-Resistant Genotypes among Clinical Isolates of with Van B Phenotype.

Rajan R Adv Biomed Res. 2023; 12:196.

PMID: 37694237 PMC: 10492609. DOI: 10.4103/abr.abr_133_21.

The effects of daptomycin on cell wall biosynthesis in Enterococcal faecalis.

Rimal B, Chang J, Liu C, Rashid R, Singh M, Kim S Sci Rep. 2023; 13(1):12227.

PMID: 37507537 PMC: 10382475. DOI: 10.1038/s41598-023-39486-8.

References
1.
Eliopoulos G, Willey S, Reiszner E, Spitzer P, Caputo G, Moellering Jr R . In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother. 1986; 30(4):532-5. PMC: 176475. DOI: 10.1128/AAC.30.4.532. View
2.
Jones R, Barry A . Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob Agents Chemother. 1987; 31(4):625-9. PMC: 174792. DOI: 10.1128/AAC.31.4.625. View
3.
Allen N, Hobbs J, Alborn Jr W . Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother. 1987; 31(7):1093-9. PMC: 174877. DOI: 10.1128/AAC.31.7.1093. View
4.
Bush L, Boscia J, Kaye D . Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1988; 32(6):877-81. PMC: 172299. DOI: 10.1128/AAC.32.6.877. View
5.
Kaatz G, Seo S, Reddy V, Bailey E, Rybak M . Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1990; 34(11):2081-5. PMC: 172003. DOI: 10.1128/AAC.34.11.2081. View